Long-term registry for new or worsening lung scarring
Part of Lungs & breathing clinical trials.
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able and willing to sign informed consent
- You are 21 years or older
- You were newly diagnosed within the last 12 months if you have IPF
- Or you have another type of interstitial lung disease that shows ongoing scarring on CT scan or biopsy, and has been “progressing” in the last 24 months
- In the past 24 months, your breathing tests and/or symptoms or CT scan findings must have worsened by specific amounts (such as a drop in FVC or DLCO, or more breathing symptoms and more scarring on imaging)
- You are not currently in an interventional drug/study trial and you’re not already on a lung transplant waiting list
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study sets up an international registry to follow people with newly diagnosed fibrotic interstitial lung disease (lung scarring). It uses eHealth technology (an online/app-based system) so your team can better understand your condition over time and improve future care.
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
This registry collects health and breathing test information from adults with autoimmune-related lung scarring (interstitial lung disease) diagnosed recently. It helps researchers better understand who has this condition and how it changes over time.
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
Hear when a new Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.